New and Recent Tools on Long Acting Injectables

TargetHIV

Potentially ground-breaking long acting injectable (LAI) HIV regimens received federal approval quite some time ago: for HIV treatment (January 2021) and HIV prevention (December 2021). Both offer the potential to simplify medication regimens and improve adherence.

The following resources, released in mid-2022, may help HIV care agencies and patients get their heads around the complexities and pick up the pace for consideration and implementation of LAI options.

HRSA will soon announce the award of Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV, a new project to develop LAI technical tools for Ryan White HIV/AIDS Program agencies.

We'd like your feedback

Was this page helpful?
I found this page helpful because the content on the page:
Check all that apply
I did not find this page helpful because the content on the page:
Check all that apply
Please include an email address if you would like a response
Please include an email address if you would like a response
Did you use this approach in your work?
Not yet because
If no, why not?